Clinic
Geisinger Wyoming Valley Medical Center
Geisinger Wyoming Valley Medical Center was paid $7.05M by Medicaid between Jan 2018 and Dec 2024, across 223 billing codes. Its largest line is 0202U, Oncology (prostate), multianalyte, gene expression profiling — 32% of everything it billed.
33Billing provider infoGEISINGER WYOMING VALLEY MEDICAL CENTER
WILKES BARRE, PA 18702
WILKES BARRE, PA 18702
33aNPI1174822068assigned 03/18/2011
33bProvider typeClinic/Center
28Total paid$7.05M
24GClaims173,307
24DCodes billed223
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinic/Center providers in Pennsylvania
Rank by total paid#25 of 176
Median peer was paid$441K
This provider vs. median16×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MULL, CINDY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 180 | $8K | |
| 2019 | 209 | $11K | |
| 2020 | 6,827 | $331K | |
| 2021 | 91,110 | $3.27M | |
| 2022 | 27,861 | $1.61M | |
| 2023 | 23,782 | $1.04M | |
| 2024incomplete | 23,338 | $784K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 32% | 9,294 | 9,006 | $2.26M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.6% | 3,070 | 2,968 | $534K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 6.6% | 3,996 | 3,860 | $465K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 6.4% | 5,872 | 5,719 | $452K |
| X0620 | 6.1% | 2,445 | 2,287 | $428K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 2.7% | 667 | 655 | $192K |
| 0100U | 2.7% | 433 | 428 | $192K | |
| 87631 | 2.3% | 1,132 | 1,110 | $160K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.1% | 669 | 665 | $151K |
| 87481 | 1.4% | 1,441 | 1,362 | $97K | |
| 80053 | Comprehensive metabolic panel | 1.3% | 8,323 | 7,936 | $95K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 1.1% | 1,920 | 1,829 | $75K |
211 more codes
| T1015 | A visit at a community health center or clinic (one all-in rate) | 1.1% | 1,587 | $74K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.0% | 1,104 | $73K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 891 | $70K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,537 | $64K |
| 95811 | <1% | 127 | $62K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 717 | $59K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,662 | $57K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 9,289 | $55K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,366 | $54K |
| 300 | Patient transfer system <300 | <1% | 447 | $50K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 772 | $50K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,073 | $48K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 336 | $43K |
| 76830 | Ultrasound, transvaginal | <1% | 638 | $41K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 385 | $38K |
| 20553 | <1% | 1,293 | $34K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,073 | $33K |
| 80061 | Lipid panel | <1% | 2,385 | $33K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 965 | $27K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 494 | $26K |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 269 | $24K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,703 | $23K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,909 | $23K |
| 76770 | <1% | 348 | $23K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 290 | $23K |
| 87430 | <1% | 3,477 | $22K | |
| Q3014 | Telehealth originating site facility fee | <1% | 1,534 | $22K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 1,170 | $22K |
| 93971 | <1% | 277 | $21K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 264 | $21K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,085 | $21K |
| 71250 | <1% | 220 | $20K | |
| 81003 | <1% | 6,610 | $20K | |
| 87150 | <1% | 423 | $19K | |
| 81025 | <1% | 4,244 | $18K | |
| 84702 | <1% | 960 | $16K | |
| 86803 | <1% | 805 | $16K | |
| 20552 | <1% | 601 | $16K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,453 | $15K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,121 | $14K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 372 | $14K |
| 76536 | <1% | 228 | $14K | |
| X0615 | <1% | 71 | $14K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 922 | $13K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,452 | $13K |
| 85027 | <1% | 1,740 | $13K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 955 | $12K |
| 87511 | <1% | 672 | $12K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,765 | $12K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 387 | $12K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 569 | $12K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 201 | $11K |
| 73564 | <1% | 381 | $11K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 7,916 | $10K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 85 | $10K |
| 82728 | <1% | 836 | $10K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 125 | $10K |
| 71045 | Radiologic examination, chest; single view | <1% | 755 | $10K |
| 93970 | <1% | 85 | $10K | |
| X0621 | <1% | 48 | $10K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 397 | $9K |
| 73610 | <1% | 377 | $9K | |
| 82607 | <1% | 709 | $9K | |
| 83690 | <1% | 1,760 | $9K | |
| 84484 | <1% | 860 | $9K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 132 | $9K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 200 | $9K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 214 | $8K |
| 73630 | <1% | 494 | $8K | |
| 72100 | <1% | 265 | $8K | |
| 83880 | <1% | 209 | $7K | |
| 83540 | <1% | 865 | $7K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,028 | $7K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 213 | $7K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 62 | $7K |
| 62323 | <1% | 89 | $7K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 51 | $7K |
| 74018 | <1% | 354 | $7K | |
| 90715 | <1% | 739 | $6K | |
| 73130 | <1% | 395 | $6K | |
| 70486 | <1% | 58 | $6K | |
| 73030 | <1% | 277 | $6K | |
| 83605 | <1% | 724 | $6K | |
| 86850 | <1% | 670 | $6K | |
| X0592 | <1% | 132 | $5K | |
| 87340 | <1% | 300 | $4K | |
| 83550 | <1% | 795 | $4K | |
| 31575 | <1% | 68 | $4K | |
| 80050 | General health panel | <1% | 87 | $4K |
| 86762 | <1% | 194 | $4K | |
| 86901 | <1% | 750 | $4K | |
| 86900 | <1% | 749 | $4K | |
| 82570 | <1% | 469 | $3K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 340 | $3K |
| 94664 | <1% | 160 | $3K | |
| 84439 | <1% | 408 | $3K | |
| 73110 | <1% | 190 | $3K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 78 | $3K |
| 97161 | <1% | 51 | $3K | |
| 27096 | <1% | 43 | $3K | |
| 87186 | <1% | 344 | $3K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 125 | $3K |
| 86618 | <1% | 117 | $3K | |
| 86003 | <1% | 18 | $3K | |
| 86780 | <1% | 162 | $3K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 124 | $3K |
| 86592 | <1% | 623 | $3K | |
| 82746 | <1% | 215 | $3K | |
| 82950 | <1% | 365 | $2K | |
| 83735 | <1% | 398 | $2K | |
| 87522 | Neg quan hep c or qual rna | <1% | 54 | $2K |
| 82248 | <1% | 329 | $2K | |
| 82805 | <1% | 57 | $2K | |
| 85379 | <1% | 201 | $2K | |
| 62321 | <1% | 25 | $2K | |
| 85610 | <1% | 514 | $2K | |
| 51798 | <1% | 147 | $2K | |
| 76870 | <1% | 29 | $2K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,648 | $2K |
| 87077 | <1% | 229 | $2K | |
| 85046 | <1% | 273 | $2K | |
| 76801 | <1% | 25 | $2K | |
| 82043 | <1% | 221 | $2K | |
| 86140 | <1% | 565 | $2K | |
| 83525 | <1% | 145 | $2K | |
| 73090 | <1% | 96 | $2K | |
| 73502 | <1% | 49 | $1K | |
| 81001 | <1% | 411 | $1K | |
| 95800 | <1% | 12 | $1K | |
| 85652 | <1% | 391 | $1K | |
| G0008 | Administration of influenza virus vaccine | <1% | 118 | $1K |
| 82962 | <1% | 640 | $1K | |
| 83520 | <1% | 65 | $1K | |
| 80081 | <1% | 12 | $1K | |
| 87088 | <1% | 119 | $1K | |
| 82565 | <1% | 158 | $1K | |
| 85007 | <1% | 211 | $959.99 | |
| 83655 | <1% | 88 | $928.60 | |
| 80076 | <1% | 103 | $917.18 | |
| 73590 | <1% | 43 | $908.14 | |
| 80074 | <1% | 15 | $778.32 | |
| 84403 | <1% | 31 | $776.43 | |
| 59025 | Fetal non-stress test | <1% | 166 | $763.83 |
| 84100 | <1% | 147 | $759.00 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 320 | $755.13 |
| J1020 | Injection, methylprednisolone acetate, 20 mg | <1% | 812 | $737.52 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,006 | $715.96 |
| 81000 | <1% | 162 | $687.13 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,877 | $666.98 |
| 73080 | <1% | 40 | $652.51 | |
| 92567 | <1% | 62 | $632.52 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 18 | $632.17 |
| 84146 | <1% | 25 | $611.28 | |
| 90686 | <1% | 82 | $591.54 | |
| 84153 | <1% | 25 | $586.25 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 14 | $533.19 |
| 83970 | <1% | 12 | $530.79 | |
| 73140 | <1% | 40 | $499.19 | |
| G0101 | Cervical or vaginal cancer screening; pelvic and clinical breast examination | <1% | 12 | $490.12 |
| 82375 | <1% | 85 | $473.41 | |
| 84156 | <1% | 112 | $470.14 | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 20 | $465.50 |
| 86038 | <1% | 33 | $458.85 | |
| 72050 | <1% | 12 | $429.92 | |
| 82550 | <1% | 53 | $384.66 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 657 | $376.94 |
| 81002 | <1% | 107 | $364.16 | |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | <1% | 31 | $361.46 |
| 12001 | <1% | 13 | $345.76 | |
| 82105 | <1% | 15 | $301.28 | |
| 29125 | <1% | 13 | $283.08 | |
| 83021 | <1% | 13 | $275.81 | |
| 69210 | <1% | 14 | $256.80 | |
| 92557 | <1% | 12 | $223.01 | |
| 86787 | <1% | 13 | $220.63 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 790 | $203.60 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 920 | $189.10 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 93 | $176.13 |
| 83050 | <1% | 57 | $164.25 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 161 | $145.22 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,852 | $136.29 |
| 86431 | <1% | 14 | $106.27 | |
| 85730 | <1% | 13 | $101.38 | |
| J2704 | Injection, propofol, 10 mg | <1% | 667 | $89.44 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 813 | $88.56 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 458 | $76.90 |
| 84550 | <1% | 13 | $72.23 | |
| 82947 | <1% | 12 | $54.04 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,462 | $40.08 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,066 | $38.20 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 294 | $18.96 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 226 | $17.68 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,402 | $12.82 |
| 36416 | <1% | 13 | $6.60 | |
| 90656 | 0% | 51 | $0.00 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 41 | $0.00 |
| C9290 | Injection, bupivacaine liposome, 1 mg | 0% | 83 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 895 | $0.00 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 169 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 130 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 283 | $0.00 |
| J8501 | Aprepitant, oral, 5 mg | 0% | 12 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 14 | $0.00 |
| J3490 | Unclassified drugs | 0% | 26 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 1,507 | $0.00 |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | 0% | 430 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 13 | $0.00 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 14 | $0.00 |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 56 | $0.00 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | 0% | 12 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 20 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMULL, CINDY (DIRECTOR)
| Provider | Location | Paid |
|---|---|---|
| Geisinger Clinic | Danville, PA | $74.54M |
| Community Medical Center | Scranton, PA | $22.62M |
| Geisinger Clinic | Danville, PA | $14.93M |
| West Shore Advanced Life Support Services, INC. | Danville, PA | $4.41M |
| Geisinger Clinic | Pottsville, PA | $3.39M |
| Geisinger Clinic | Lewistown, PA | $2.93M |
| Geisinger Clinic | Scranton, PA | $2.63M |
| Geisinger Clinic | Wilkes Barre, PA | $2.35M |
| Geisinger Clinic | Danville, PA | $2.28M |
| Geisinger Jersey Shore Hospital | Jersey Shore, PA | $2.17M |
| Geisinger Clinic | Scranton, PA | $1.71M |
| Geisinger Clinic | Tunkhannock, PA | $1.11M |
| Geisinger Clinic | Orwigsburg, PA | $974K |
| Geisinger Clinic | Pittston, PA | $942K |
| Geisinger Clinic | Berwick, PA | $896K |
| Geisinger Clinic Selinsgrove | Selinsgrove, PA | $819K |
| Geisinger Clinic | Philipsburg, PA | $678K |
| Geisinger Clinic | Lewisburg, PA | $557K |
| Geisinger Clinic | Mountain Top, PA | $523K |
| Geisinger Clinic | Kulpmont, PA | $489K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.